Opendata, web and dolomites

Magicbullet Reloaded SIGNED

Small-Molecule Drug Conjugates for Targeted Delivery in Tumor Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Magicbullet Reloaded project word cloud

Explore the words cloud of the Magicbullet Reloaded project. It provides you a very rough idea of what is the project "Magicbullet Reloaded" about.

smdcs    expanded    basis    biology    peptide    discovery    made    cells    synthesize    investigation    pipeline    acquired    conjugates    implication    overcome    recruited    nobel    environment    complementarity    pdcs    cell    interdisciplinary    compound    academia    laureate    paul    magic    title    causing    vice    substantially    continuing    drugs    antigens    bold    organism    direction    grant    magicbullet    small    despite    perfectly    physiology    bullet    tissue    industry    death    selectively    vision    2018    efforts    pharmacology    worldwide    pharmacokinetic    ideal    therapy    outstanding    resistance    molecule    reloaded    disease    had    drug    immuno    brings    therapeutic    medicinal    2015    premature    642004    etn    organic    stimulate    1908    builds    kills    successful    efficient    special    biochemistry    esrs    consequence    versa    tumor    scientific    expand    exposed    cancer    ehrlich    delivered    chemistry    array    faceted    idea    broad    immune    agent    expert    selectivity    toxin    refers    antitumor    competences    treatments   

Project "Magicbullet Reloaded" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET BIELEFELD 

Organization address
address: UNIVERSITAETSSTRASSE 25
city: BIELEFELD
postcode: 33615
website: www.uni-bielefeld.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙915˙902 €
 EC max contribution 3˙915˙902 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2023-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET BIELEFELD DE (BIELEFELD) coordinator 252˙788.00
2    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 303˙172.00
3    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 281˙276.00
4    PHILOCHEM AG CH (OTELFINGEN) participant 281˙276.00
5    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 280˙805.00
6    EXIRIS SRL IT (ROMA) participant 261˙499.00
7    TAKIS SRL IT (ROMA) participant 261˙499.00
8    UNIVERSITA DEGLI STUDI DELL'INSUBRIA IT (VARESE) participant 261˙499.00
9    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 261˙499.00
10    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 252˙788.00
11    HEIDELBERG PHARMA RESEARCH GMBH DE (LADENBURG) participant 252˙788.00
12    TECHNISCHE UNIVERSITAT DARMSTADT DE (DARMSTADT) participant 252˙788.00
13    UNIVERSITAET ZU KOELN DE (KOELN) participant 252˙788.00
14    EOTVOS LORAND TUDOMANYEGYETEM HU (BUDAPEST) participant 229˙715.00
15    Orszagos Onkologiai Intezet HU (Budapest) participant 229˙715.00

Map

 Project objective

'Despite the continuing development of new and more efficient treatments, cancer remains the second cause of premature death worldwide. Multi-faceted interdisciplinary research efforts in industry and academia on different aspects of cancer have provided a knowledge basis for the development of novel therapeutic approaches. Paul Ehrlich, Nobel laureate in Physiology of 1908, had the early vision that a compound could be made to selectively target a disease-causing organism or tumor. A toxin for the particular tissue could be delivered by an agent of selectivity. Such an ideal therapeutic agent would be a 'magic bullet' that only kills the target cells. This ETN initiative with the title Magicbullet::reloaded refers to Ehrlich’s bold idea and builds on the previous experience of the highly successful ETN MAGICBULLET (2015-2018, grant agreement No. 642004). As a consequence of the outstanding results, the ETN Magicbullet::reloaded will expand the field of investigation from peptide-drug conjugates (PDCs) to small molecule-drug conjugates (SMDCs) with a special focus on drugs capable to stimulate tumor immune responses and overcome resistance to immuno-therapy. The consortium has been substantially expanded to perfectly address the needs of the new research direction. The planned ETN will design and synthesize an array of SMDCs (including PDCs), also targeting less investigated tumor antigens, investigate their pharmacokinetic behaviour, their implication on the immune system, as well as their tumor selectivity and antitumor activity. The consortium brings together interdisciplinary expert knowledge in Organic Chemistry, Peptide Chemistry, Medicinal Chemistry, Drug Discovery, Biochemistry, Pharmacology and Cell Biology. This high complementarity is required for the different scientific tasks in the development pipeline. Vice versa, the recruited ESRs will be exposed to a challenging research environment leading to a broad range of scientific competences to be acquired.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGICBULLET RELOADED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGICBULLET RELOADED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

WON (2019)

Wideband Optical Networks

Read More